Revolution Medicines, Inc. (NASDAQ:RVMDW – Get Free Report) was the target of a significant drop in short interest in the month of July. As of July 31st, there was short interest totaling 1,153 shares, a drop of 47.6% from the July 15th total of 2,202 shares. Based on an average daily volume of 16,349 shares, the short-interest ratio is presently 0.1 days.
Revolution Medicines Stock Up 10.9%
Shares of NASDAQ:RVMDW traded up $1.21 on Monday, hitting $12.31. 55,455 shares of the company’s stock were exchanged, compared to its average volume of 116,236. Revolution Medicines has a 12 month low of $0.16 and a 12 month high of $12.37. The business’s 50 day simple moving average is $8.79 and its two-hundred day simple moving average is $5.21.
About Revolution Medicines
Revolution Medicines (NASDAQ:RVMDW) is a clinical-stage oncology company focused on discovering and developing small-molecule therapies that target the RAS signaling pathway. The company’s scientific approach centers on designing molecules that selectively inhibit mutant RAS proteins and key regulators of RAS-driven cancers, with the goal of addressing tumor types that have historically been resistant to targeted therapies.
Revolution Medicines has advanced multiple pipeline candidates into clinical trials, including RMC-4630, a selective SHP2 inhibitor, and RMC-6236, an oral pan-RAS inhibitor designed to block signaling from multiple RAS mutants.
See Also
- Five stocks we like better than Revolution Medicines
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
- D-Wave Has Momentum—What Does It Need to Keep It Going?
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
